adverse reaction to omalizumab in patients with chronic urticaria: flare up or ineffectiveness?

نویسندگان

ragıp ertaş kayseri education and research hospital, department of dermatology and venereology, kayseri, turkey

kemal özyurt kayseri education and research hospital, department of dermatology and venereology, kayseri, turkey

sinem yıldız kayseri education and research hospital, department of dermatology and venereology, kayseri, turkey

yılmaz ulaş kayseri education and research hospital, department of dermatology and venereology, kayseri, turkey

چکیده

omalizumab is a recombinant humanized anti-ig e monoclonal antibody used as the third line treatment of chronic spontaneous urticaria (csu). we report four patients with severe antihistamine-resistant csu, who developed angioedema, anaphylaxis and/or flare up of urticaria at different times following omalizumab therapy.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Effects of Omalizumab Treatment in Patients With Refractory Chronic Urticaria

PURPOSE Chronic urticaria (CU) is a common and debilitating disease, and the need for effective treatment has increased. Omalizumab may be an alternative regimen in patients with CU who do not respond to conventional treatments. The aim of this study is to investigate the efficacy and to observe the clinical results of omlizumab in patients with refractory CU. METHODS We conducted a retrospec...

متن کامل

Unpredicted adverse reaction to omalizumab.

Despite promising reports of the use of omalizumab as add-on therapy in patients with systemic mastocytosis and recurrent anaphylaxis during specific venom immunotherapy (VIT), unpredicted adverse effects may lead to therapy failure. We present the case of a patient with systemic mastocytosis and Hymenoptera venom allergy who was administered omalizumab as add-on therapy to improve VIT tolerabi...

متن کامل

269 Refractory Chronic Urticaria Treated with Omalizumab

269 Refractory Chronic Urticaria Treated with Omalizumab Martinez Saenz, NP, Ramírez Del Pozo, ME, Lopez Tiro JJ, and Javier Gomez Vera, MD. Alergia e inmunologia clínica, Hospital Regional Lic. Adolfo Lopez Mateos, Distrito Federal, Mexico. Background: Chronic urticaria (CU) is a common disorder characterized by recurrent episodes of urticaria pruritic erythematous lesions, associated with ang...

متن کامل

Chronic idiopathic urticaria: treatment with omalizumab.

Chronic idiopathic urticaria (CIU) is a common autoimmune skin condition characterized by spontaneously recurring hives for 6 weeks or longer. The new terminology used for CIU in most countries including Canada is chronic spontaneous urticaria (CSU). CSU is associated with significant psychosocial morbidity with a markedly negative impact on overall quality of life. Conventional approaches with...

متن کامل

Psychological status in patients with chronic urticaria

 Abstract Background: Chronic urticaria (CU) is a common dermatological disease that induces a substantial burden on individuals’ life. Also if one’s self-image changes (which usually happen in patients with dermatological diseases), it leads to anxiety or other various symptoms. We aimed to compare the psychological scales in patients with CU with non-dermatological individuals with the purpos...

متن کامل

Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

BACKGROUND Many patients with chronic idiopathic urticaria (also called chronic spontaneous urticaria) do not have a response to therapy with H-antihistamines, even at high doses. In phase 2 trials, omalizumab, an anti-IgE monoclonal antibody [corrected] that targets IgE and affects mast-cell and basophil function, has shown efficacy in such patients. METHODS In this phase 3, multicenter, ran...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
iranian journal of allergy, asthma and immunology

جلد ۱۵، شماره ۱، صفحات ۸۲-۸۶

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023